NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
NeuBase |
Data show that Stealth Editors achieve ex vivo gene editing using simple synthetic reagents to harness the cells own high-fidelity editing machineryData show that Stealth Editors do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an or
Read at finance.yahoo.com
 |
NeuBase Therapeutics Fundamental Analysis
We analyze NeuBase Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
NeuBase Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
NeuBase Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeuBase Therapeutics stock to make a market-neutral strategy. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics with similar companies.
Peers
NeuBase Therapeutics Related Equities
| PHGE | Biomx | 2.82 | ||||
| CMPX | Compass Therapeutics | 1.84 | ||||
| SONN | Sonnet Biotherapeutics | 1.56 | ||||
| NAMS | NewAmsterdam Pharma | 1.06 | ||||
| GLUE | Monte Rosa | 1.35 | ||||
| IVA | Inventiva | 1.51 | ||||
| CGEM | Cullinan Oncology | 2.08 | ||||
| ZVSA | ZyVersa Therapeutics | 3.74 | ||||
| IMMX | Immix Biopharma | 4.74 | ||||
| CNSP | Cns Pharmaceuticals | 8.33 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |